SCHEMBL3371679

SCHEMBL3371679

O=C1c2cccc(O)c2C(=O)N1c1ccc(C(F)(C(F)(F)F)C(F)(F)F)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ANPEP P15144 2/20 0.48
DPP4 P27487 2/20 0.48
ADORA2A P29274 1/20 0.43
HSPA1A P0DMV8 1/20 0.43
PABPC1 P11940 1/20 0.43
TYMS P04818 2/20 0.41
MEN1 O00255 2/20 0.40
USP2 O75604 2/20 0.40
KMT2A Q03164 2/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
TNNI3 P19429 1/20 0.40
HTT P42858 1/20 0.40
TNNT2 P45379 1/20 0.40
TNNC1 P63316 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
AHR P35869 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
ATM Q13315 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3373435 0.89 ANPEP (0.48) ANPEPDPP4ADORA2AHSPA1APABPC1
SCHEMBL3373539 0.89 ANPEP (0.54) ANPEPDPP4ADORA2AHSPA1APABPC1
SCHEMBL3374587 0.81 ANPEP (0.46) ANPEPDPP4TYMSLMNASMN1; SMN2
SCHEMBL6441097 0.81 POLB (0.58) ANPEPDPP4ADORA2AHSPA1APABPC1
SCHEMBL3376342 0.80 CCR9 (0.47) ANPEPDPP4ADORA2AHSPA1APABPC1
SCHEMBL3373168 0.79 HPGD (0.41) ADORA2AHSPA1APABPC1TYMSMEN1
SCHEMBL9630664 0.77 ANPEP (0.56) ANPEPDPP4ADORA2AHSPA1APABPC1
SCHEMBL3376897 0.76 ADORA2A (0.40) ADORA2AHSPA1APABPC1TYMSAHR
SCHEMBL3377819 0.74 ADORA2A (0.39) ADORA2AHSPA1APABPC1TYMSMEN1
SCHEMBL9952239 0.74 CCR9 (0.48) ANPEPDPP4TYMSMEN1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1517886-B1 NOVEL PHTHALAMIDE DERIVATIVES BAYER CROPSCIENCE AG (DE) 2010-11-10 EP disclosed
US-7132455-B2 Phthalamide derivatives BAYER CROPSCIENCE AG (DE) 2006-11-07 US disclosed
US-20060035967-A1 Novel phthalamide derivatives BAYER INTELLECTUAL PROPERTY GMBH (DE) 2006-02-16 US disclosed
EP-1517886-A1 NOVEL PHTHALAMIDE DERIVATIVES Bayer CropScience AG (DE) 2005-03-30 EP disclosed
WO-2004000796-A1 NOVEL PHTHALAMIDE DERIVATIVES BAYER CROPSCIENCE AG (DE) 2003-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035967-A1 Novel phthalamide derivatives HDAC1, HDAC2, CRY1 ANPEP 3368/4885DPP4 1795/4885ADORA2A 4559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.